Valneva to Present and Hold Investor Meetings at Upcoming Conferences in JuneGlobeNewsWire • 06/04/24
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious DiseasesGlobeNewsWire • 06/03/24
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya VaccineGlobeNewsWire • 05/13/24
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/07/24
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FGlobeNewsWire • 03/25/24
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.GlobeNewsWire • 03/21/24
Valneva Reports Full Year 2023 Results and Provides Business Updates and OutlookGlobeNewsWire • 03/20/24
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMedGlobeNewsWire • 03/18/24
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor ConferencesGlobeNewsWire • 03/04/24
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®GlobeNewsWire • 02/29/24
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 GuidanceGlobeNewsWire • 02/15/24
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya VaccineGlobeNewsWire • 01/10/24
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF ForumGlobeNewsWire • 01/04/24
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of DirectorsGlobeNewsWire • 12/20/23
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15GlobeNewsWire • 12/04/23
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®GlobeNewsWire • 12/04/23